BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 10477593)

  • 1. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity.
    Smythe JA; Fink PD; Logan GJ; Lees J; Rowe PB; Alexander IE
    J Immunol; 1999 Sep; 163(6):3239-49. PubMed ID: 10477593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progress.
    Byrne SN; Halliday GM
    Cancer Immunol Immunother; 2003 Jun; 52(6):396-402. PubMed ID: 12739069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
    Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
    Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
    Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-species costimulation: relative contributions of CD80, CD86, and CD40.
    Rogers NJ; Jackson IM; Jordan WJ; Hawadle MA; Dorling A; Lechler RI
    Transplantation; 2003 Jun; 75(12):2068-76. PubMed ID: 12829914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
    Ilkovitch D; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD40 can costimulate human memory T cells and favors IL-10 secretion.
    Rogers NJ; Jackson IM; Jordan WJ; Lombardi G; Delikouras A; Lechler RI
    Eur J Immunol; 2003 Apr; 33(4):1094-104. PubMed ID: 12672076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.
    Sridevi K; Neena K; Chitralekha KT; Arif AK; Tomar D; Rao DN
    Int Immunopharmacol; 2004 Jan; 4(1):1-14. PubMed ID: 14975355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of costimulatory molecules CD80 and/or CD86 by a Kaposi's sarcoma tumor cell line induces differential T-cell activation and proliferation.
    Foreman KE; Wrone-Smith T; Krueger AE; Nickoloff BJ
    Clin Immunol; 1999 Jun; 91(3):345-53. PubMed ID: 10370381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exogenous and endogenous antigens are differentially presented by mast cells to CD4+ T lymphocytes.
    Frandji P; Tkaczyk C; Oskeritzian C; David B; Desaymard C; Mécheri S
    Eur J Immunol; 1996 Oct; 26(10):2517-28. PubMed ID: 8898968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.
    Fields PE; Finch RJ; Gray GS; Zollner R; Thomas JL; Sturmhoefel K; Lee K; Wolf S; Gajewski TF; Fitch FW
    J Immunol; 1998 Nov; 161(10):5268-75. PubMed ID: 9820499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
    Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
    J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of CD80 (B7.1) and CD86 (B7.2) in the immune response to an intracellular pathogen.
    Subauste CS; de Waal Malefyt R; Fuh F
    J Immunol; 1998 Feb; 160(4):1831-40. PubMed ID: 9469444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of CD80, CD86 and CD70 on T cells from HIV-infected individuals upon activation in vitro: regulation by CD4+ T cells.
    Wolthers KC; Otto SA; Lens SM; Kolbach DN; van Lier RA; Miedema F; Meyaard L
    Eur J Immunol; 1996 Aug; 26(8):1700-6. PubMed ID: 8765009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A triad of costimulatory molecules synergize to amplify T-cell activation.
    Hodge JW; Sabzevari H; Yafal AG; Gritz L; Lorenz MG; Schlom J
    Cancer Res; 1999 Nov; 59(22):5800-7. PubMed ID: 10582702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of CD86/CD28 and CD40/CD154 pathways in regulating monocyte-derived CD80 expression during their interaction with allogeneic endothelium.
    Wang P; Liu Z; Wu C; Zhu B; Wang Y; Xu H
    Transplant Proc; 2008 Oct; 40(8):2729-33. PubMed ID: 18929847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmunity without diabetes in transgenic mice expressing beta cell-specific CD86, but not CD80: parameters that trigger progression to diabetes.
    Guerder S; Eynon EE; Flavell RA
    J Immunol; 1998 Sep; 161(5):2128-40. PubMed ID: 9725204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
    La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
    J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct effects of CD86-mediated costimulation on resting versus activated human CD4+ T cells.
    Rogers NJ; Game DS; Camara NO; Jackson IM; Lombardi G; Lechler RI
    Eur J Immunol; 2005 Oct; 35(10):2909-19. PubMed ID: 16180251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.